Vaxcyte
San Francisco Bay Area Poised for Continued Life Sciences Expansion in 2025
The San Francisco Bay Area remains one of the most dynamic life sciences markets in the United States, bolstered by strong institutional backing,...
San Francisco Peninsula R&D Market Faces Challenges but Signals Potential Rebound in 2025
The San Francisco Peninsula R&D market continued to experience challenges in the fourth quarter of 2024, with net absorption recording negative 343,548 square...
Life Sciences in the San Francisco Bay Area: Surging VC Funding, New Developments, and Rising Vacancies
The San Francisco Bay Area has long been a powerhouse in the life sciences industry, home to some of the world’s most innovative...
Vaxcyte Signs Long-Term 258,600 SQFT Lease at Alexandria Center for Life Science in San Carlos
PASADENA, Calif., Nov. 21, 2024 — Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer...
Vaxcyte to Take 38,200 SQFT in Sublease Deal at the Alexandria Center for Life Sciences in San Carlos
By The Registry Staff A vaccine developer continues to expand its footprint in the Bay Area. Vaxcyte Inc. will sublease 38,200 square feet...
Vaxcyte Subleases 36,000 SQFT of Office and Research Space from Codexis in San Carlos
By The Registry Staff A clinical stage vaccine company is expanding its footprint in the Bay Area. Vaxcyte Inc., known for its efforts...
